Breaking News

Sidley Austin Adds Life Sciences Partner

May 12, 2014

Zucker joins Palo Alto office

Sam Zucker has been named partner at Sidley Austin for the Life Sciences and Corporate Emerging Companies and Venture Capital practice groups based in Palo Alto. Mr. Zucker will focus on corporate transactions for high growth life sciences and healthcare technology companies in the U.S., Asia, and around the world.
Mr. Zucker’s main areas of expertise are M&A and financings, including joint ventures, strategic alliances, and partnerships. He has also represented companies and investors in numerous financings, including venture capital and private equity as well as IPOs, follow-on offerings, and PIPEs. Mr. Zucker has extensive experience with securities regulatory and policy matters, and advising clients’ on corporate governance and critical strategic matters.
“Sam’s proven success in handling corporate transactions for clients in the life sciences and healthcare sector will make him a valuable asset to our clients and significantly enhance the counsel we currently provide,” said Paul E. Kalb, a member of Sidley’s Executive Committee and a global coordinator of the firm’s Life Sciences practice. “We look forward to leveraging Sam’s deep knowledge and insights on behalf of our clients.”
“We are delighted to welcome a lawyer with Sam’s high level of experience leading corporate transactions for clients in the life sciences and healthcare area,” said Tom DeFilipps, managing partner of Sidley’s Palo Alto office. “Sam’s strong mix of transactional skills and sector-based knowledge will enhance our client offerings, and we look forward to him playing a key role in the expansion of our life sciences and healthcare capabilities in Northern California, as well as across the firm.”
blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus